Chiome Bioscience
4583.TTSE GROWTHPharmaceutical
Financials · Standalone
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥593m | ¥781m | ¥682m | ¥631m | ¥713m | ¥481m |
| Operating income | −¥980m | −¥1.0bn | −¥1.2bn | −¥1.3bn | −¥1.3bn | — |
| Ordinary income | −¥989m | −¥1.0bn | −¥1.2bn | −¥1.2bn | −¥1.3bn | −¥1.3bn |
| Total assets | ¥1.7bn | ¥2.5bn | ¥1.8bn | ¥2.2bn | ¥2.3bn | ¥3.5bn |
| Net assets / equity | ¥1.1bn | ¥1.9bn | ¥1.2bn | ¥1.8bn | ¥1.9bn | ¥3.1bn |
| Operating cash flow | −¥936m | −¥1.0bn | −¥1.1bn | −¥1.2bn | −¥1.1bn | −¥1.4bn |
| EPS (basic) | ¥-14.47 | ¥-17.54 | ¥-24.62 | ¥-28.26 | ¥-36.74 | ¥-36.06 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 15
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 68 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 109 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 65 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 111 figures · EDINET |
| 2023-01-01 → 2023-12-31 | AnnualAmended | 112 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 68 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 46 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 112 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 48 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2Amended | 69 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 69 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 46 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 111 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 48 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 68 figures · EDINET |
23 more reports are still being processed.